secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102399
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025
--------------------------------------------------------------------------------

- Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.
- Positive ORIGIN 3 trial: 46% proteinuria reduction with atacicept; 42% vs placebo (p<0.0001).
- BLA submission for accelerated approval of atacicept in IgAN expected Q4 2025; commercial launch targeted 2026.
- Secured up to $500M credit facility with Oxford Finance, extending cash runway past potential launch.
- Initiated PIONEER basket trial for atacicept in expanded IgAN, pMN, FSGS, and MCD populations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/0000950170-25-102399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/vera-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer